ST3GAL5 and melanoma: Our loss-of-function experiments, including CRISPR/Cas9 genome-wide editing and transient shRNA-mediated knockdown of glycosphingolipid-related genes, along with in vivo studies on HiGom treatment in ST3GAL5-deficient xenograft melanoma models, confirmed that glycosphingolipid biosynthesis was crucial for the efficacy of gomesin.